Citation
Chacon-Quiros M, Sforza M, Solis-Chaves P, Herrera-Mora G, Botti G, Munhoz AM, Verdonck K, Nagumo Y, D'Incelli RC, Villalobos-Alpizar J, Clausen-Oreamuno C, Randquist C. The 3-year results of a 100-patient prospective study of the safety and effectiveness of Mia Femtech. Aesthet Surg J. 2026;46(3):250-259. doi: 10.1093/asj/sjaf196
Disclosure
Dr. Epstein is a paid investigator in the Motiva U.S. FDA clinical trial and is compensated by Establishment Labs to train surgeons on the Preservé breast augmentation technique. He discloses this relationship in all public communications involving Motiva or Preservé. Dr. Epstein owns stock in Establishment Labs.
What This Study Found
Following 100 patients for 3 years after a minimally invasive, tissue-preserving augmentation done through a small incision in the underarm, three out of four gained one to three cup sizes, the overall complication rate was 3.2%, and no patient reported any loss of nipple or breast sensation.
Key Findings
- 100 patients, IRB-approved prospective study, 3-year follow-up
- 3% achieved a 1 to 3 cup size increase
- Overall complication rate (Kaplan-Meier): 3.2%
- 93% follow-up compliance
- Zero reports of: nipple or breast sensation loss, implant rupture, Grade III/IV capsular contracture, infection, seroma, rippling, hematoma, or BIA-ALCL
- A randomized MRI sub-study of 33 patients confirmed the clinical findings
- Patient satisfaction (BREAST-Q) and scar appearance (POSAS) both improved versus conventional augmentation, with faster recovery
Why This Matters for Preservé Patients
This is the strongest sensation-preservation data in the tissue-preservation literature, useful for anyone specifically concerned about losing nipple sensitivity after augmentation.
